ImmunityBio, Inc. (IBRX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à San Diego, CA, United States. Le PDG actuel est Richard Gerald Adcock.
IBRX a date d'introduction en bourse 2015-07-28, 671 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $7.81B.
ImmunityBio, Inc. is a clinical-stage biotechnology company headquartered in San Diego that develops immunotherapies and vaccines for cancer and infectious diseases. The company's pipeline includes advanced immunotherapy and cell therapy platforms, featuring antibody-cytokine fusion proteins, synthetic immunomodulators, natural killer cells, and T cell therapies, with multiple candidates in Phase II and III clinical trials for liquid and solid tumors such as bladder, pancreatic, and lung cancers, as well as viral pathogens including SARS-CoV-2 and HIV. ImmunityBio has established strategic partnerships with leading research institutions including the National Cancer Institute and collaboration or licensing agreements with multiple biotechnology and healthcare organizations to advance its therapeutic pipeline.
